Literature DB >> 26197446

Silent Crohn's Disease: Asymptomatic Patients with Elevated C-reactive Protein Are at Risk for Subsequent Hospitalization.

Benjamin Click1, Eric J Vargas, Alyce M Anderson, Siobhan Proksell, Ioannis E Koutroubakis, Claudia Ramos Rivers, Jana G Hashash, Miguel Regueiro, Andrew Watson, Michael A Dunn, Marc Schwartz, Jason Swoger, Leonard Baidoo, Arthur Barrie, David G Binion.   

Abstract

BACKGROUND: Patient-reported Crohn's disease (CD) symptoms and endoscopic evaluation have historically guided routine care, but the risk of complications in asymptomatic patients with elevated C-reactive protein (CRP) is unknown.
METHODS: We conducted a prospective observational cohort study of patients with CD from a tertiary care center. Subjects with short inflammatory bowel disease questionnaire scores ≥ 50, Harvey-Bradshaw CD scores ≤ 4, and same-day CRP measurement were eligible for inclusion. The primary outcome was disease-related hospitalization up to 24 months after the qualifying clinic visit. We assessed the relationship between CRP elevation and subsequent hospitalization.
RESULTS: There were 351 asymptomatic patients with CD (median age 40 yr; 50.4% female) who met inclusion criteria, and CRP was elevated in 19.7% of these individuals (n = 69). At 24 months, 16.8% (n = 59) of the study population had been hospitalized for CD-related complications. Significantly, more patients with an elevated CRP were hospitalized (33.3% versus 12.8%, P < 0.0001) compared with those with a normal CRP and were hospitalized at increased rate (P < 0.001) on Kaplan-Meier analysis. CRP elevation was significantly and independently associated with increased risk of hospitalization (adjusted hazard ratio 2.12; 95% confidence interval, 1.13-3.98; P = 0.02) in multivariable survival analysis.
CONCLUSIONS: Asymptomatic patients with CD with elevated CRP are at a nearly 2-fold higher risk for hospitalization over the subsequent 2 years compared with asymptomatic patients with CD without CRP elevation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26197446     DOI: 10.1097/MIB.0000000000000516

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  15 in total

Review 1.  Current best practice for disease activity assessment in IBD.

Authors:  Alissa J Walsh; Robert V Bryant; Simon P L Travis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-01       Impact factor: 46.802

2.  Factors That Predict High Health Care Utilization and Costs for Patients With Inflammatory Bowel Diseases.

Authors:  Julajak Limsrivilai; Ryan W Stidham; Shail M Govani; Akbar K Waljee; Wen Huang; Peter D R Higgins
Journal:  Clin Gastroenterol Hepatol       Date:  2016-09-17       Impact factor: 11.382

3.  A Low Neutrophil CD64 Index Is Associated with Sustained Remission During Infliximab Maintenance Therapy.

Authors:  Phillip Minar; Kimberly Jackson; Yi-Ting Tsai; Michael J Rosen; Michael Northcutt; Marat Khodoun; Fred D Finkelman; Lee A Denson
Journal:  Inflamm Bowel Dis       Date:  2016-11       Impact factor: 5.325

Review 4.  Mucosal Healing in Crohn's Disease: Bull's Eye or Bust? "The Pro Position".

Authors:  Neil O'Moráin; Jayne Doherty; Roisin Stack; Glen A Doherty
Journal:  Inflamm Intest Dis       Date:  2021-11-03

Review 5.  Approach to the Patient with Mild Crohn's Disease: a 2016 Update.

Authors:  Frank I Scott; Gary R Lichtenstein
Journal:  Curr Gastroenterol Rep       Date:  2016-09

6.  Development of an Inflammatory Bowel Disease Research Registry Derived from Observational Electronic Health Record Data for Comprehensive Clinical Phenotyping.

Authors:  Alyce J M Anderson; Benjamin Click; Claudia Ramos-Rivers; Dmitriy Babichenko; Ioannis E Koutroubakis; Douglas J Hartman; Jana G Hashash; Marc Schwartz; Jason Swoger; Arthur M Barrie; Michael A Dunn; Miguel Regueiro; David G Binion
Journal:  Dig Dis Sci       Date:  2016-09-12       Impact factor: 3.199

7.  Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn's disease.

Authors:  Kyunghwan Oh; Eun Hye Oh; Seunghee Baek; Eun Mi Song; Gwang-Un Kim; Myeongsook Seo; Sung Wook Hwang; Sang Hyoung Park; Dong-Hoon Yang; Kyung-Jo Kim; Jeong-Sik Byeon; Seung-Jae Myung; Suk-Kyun Yang; Byong Duk Ye
Journal:  PLoS One       Date:  2017-06-16       Impact factor: 3.240

8.  Homozygosity for the SCN10A Polymorphism rs6795970 Is Associated With Hypoalgesic Inflammatory Bowel Disease Phenotype.

Authors:  Eugene Gonzalez-Lopez; Yuka Imamura Kawasawa; Vonn Walter; Lijun Zhang; Walter A Koltun; Xuemei Huang; Kent E Vrana; Matthew D Coates
Journal:  Front Med (Lausanne)       Date:  2018-11-27

9.  Monocytosis Is a Biomarker of Severity in Inflammatory Bowel Disease: Analysis of a 6-Year Prospective Natural History Registry.

Authors:  Alyce Anderson; Cynthia Cherfane; Benjamin Click; Claudia Ramos-Rivers; Ioannis E Koutroubakis; Jana G Hashash; Dmitriy Babichenko; Gong Tang; Michael Dunn; Arthur Barrie; Siobhan Proksell; Jeffrey Dueker; Elyse Johnston; Marc Schwartz; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2022-01-05       Impact factor: 5.325

10.  Elevated C-reactive protein is associated with disease progression in patients with mild Crohn's disease.

Authors:  Min Seob Kwak; Kyung-Jo Kim; Sang Hyoung Park; Dong-Hoon Yang; Byong Duk Ye; Jeong-Sik Byeon; Seung-Jae Myung; Suk-Kyun Yang
Journal:  Springerplus       Date:  2016-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.